文献速递乳腺癌

哌柏西利联合内分泌治疗对比卡培他滨用于激素受体阳性、HER2阴性绝经前转移性乳腺癌女性(Young-PEARL):一项随机、开放标签、2期研究的总生存分析

Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.
PubMed 文献 · Lancet Oncol · 2025-02-17

Young-PEARL研究在韩国14家机构纳入绝经前激素受体阳性、HER2阴性转移性乳腺癌患者,随机接受哌柏西利联合依西美坦及卵巢功能抑制或卡培他滨。中位随访54.0个月,联合组中位无进展生存期19.5个月 vs 卡培他滨组14.0个月(HR 0.74,90%CI 0.57-0.98,单侧p=0.036),但总生存无显著改善(HR 1.02,95%CI 0.69-1.51,p=0.92)。

要点

  • 哌柏西利联合内分泌治疗较卡培他滨显著延长无进展生存期,但总生存无显著差异。
  • 哌柏西利联合内分泌治疗组3级及以上中性粒细胞减少发生率为64%,卡培他滨组为18%。
  • 作者认为哌柏西利联合内分泌治疗为绝经前患者首选,卡培他滨优先策略在资源有限地区可作为替代。

核心结论

  • 在延长随访后,哌柏西利联合依西美坦及卵巢功能抑制对比卡培他滨,在既往接受过他莫昔芬治疗的绝经前激素受体阳性、HER2阴性转移性乳腺癌患者中持续显示无进展生存期显著获益,但未观察到总生存改善。
  • 作者认为,鉴于无进展生存期获益,哌柏西利联合内分泌治疗是绝经前女性的首选选择,尽管在资源有限地区卡培他滨优先策略可能是维持总生存的替代治疗策略。

研究设计与样本

  • Young-PEARL是一项在韩国14家机构开展的多中心、随机、开放标签、2期研究。
  • 纳入年龄19岁及以上、组织学确诊的激素受体阳性、HER2阴性转移性乳腺癌绝经前女性,患者须在既往他莫昔芬治疗期间或之后复发或进展、未接受过芳香化酶抑制剂、ECOG体能状态评分为0-2,允许在转移阶段接受过一线化疗。
  • 患者按1:1随机分配,采用区组随机化(区组大小为2),按既往转移性乳腺癌化疗和内脏转移分层,分别接受哌柏西利(口服,每日125 mg,服药3周停药1周)联合依西美坦(口服,每日25 mg)及亮丙瑞林(皮下注射,每个28天周期第1天3.75 mg)或卡培他滨(口服,1250 mg/m2,每日两次,服药2周停药1周),直至疾病进展或不可耐受的毒性。
  • 主要终点为无进展生存期,总生存期为次要终点;所有分析在改良意向治疗人群中进行,安全性在所有接受任何研究治疗的患者中评估。

主要发现

  • 2016年6月15日至2018年12月10日期间共入组189例患者,184例随机分配至哌柏西利联合内分泌治疗组(n=92)或卡培他滨组(n=92),其中174例纳入改良意向治疗人群(哌柏西利联合内分泌治疗组n=90,卡培他滨组n=84)。
  • 截至数据截止日2024年2月29日,中位随访时间为54.0个月(IQR 34.1-74.4)。
  • 哌柏西利联合内分泌治疗组中位无进展生存期为19.5个月(90%CI 14.3-22.2),卡培他滨组为14.0个月(90%CI 11.7-18.7),风险比(HR)为0.74(90%CI 0.57-0.98),单侧log-rank p=0.036。
  • 哌柏西利联合内分泌治疗组90例中52例(58%)死亡,卡培他滨组84例中48例(57%)死亡;中位总生存期哌柏西利联合内分泌治疗组为54.8个月(95%CI 48.9-77.1),卡培他滨组为57.8个月(95%CI 46.3-89.2),HR为1.02(95%CI 0.69-1.51),p=0.92。
  • 最常见的3级或更严重不良事件为中性粒细胞减少:哌柏西利联合内分泌治疗组92例中59例(64%),卡培他滨组85例中15例(18%);未发生治疗相关死亡。

临床怎么用

  • 作者认为,鉴于无进展生存期获益,哌柏西利联合内分泌治疗是绝经前激素受体阳性、HER2阴性转移性乳腺癌女性的首选选择。
  • 作者认为,在资源有限地区,卡培他滨优先策略可能是维持总生存的替代治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase 2 randomised Young-PEARL study demonstrated that palbociclib plus exemestane with ovarian function suppression significantly prolonged progression-free survival compared with capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Here, we report results of the protocol-specified secondary endpoint of overall survival. METHODS: Young-PEARL was a multicentre, randomised, open-label, phase 2 study conducted at 14 institutions in South Korea. Premenopausal women aged 19 years or older with histologically confirmed hormone receptor-positive, HER2-negative metastatic breast cancer that recurred or progressed during or after previous tamoxifen treatment, who were aromatase inhibitor naive, and had an Eastern Cooperative Oncology Group performance status of 0-2 were eligible. One previous line of chemotherapy was permitted in the metastatic setting. Eligible patients were randomly assigned (1:1), using block randomisation (block size of two) stratified by previous chemotherapy for metastatic breast cancer and presence of visceral metastasis, to receive either palbociclib (orally, 125 mg per day on a 3-weeks-on, 1-week off schedule) plus exemestane (orally 25 mg daily) with leuprorelin (subcutaneously 3·75 mg on day 1 of each 28-day cycle) or capecitabine (orally, 1250 mg/m2 twice a day on a 2-weeks-on, 1-week-off schedule) until disease progression or unacceptable toxicity). The primary endpoint was progression-free survival. Overall survival was a secondary endpoint. All analyses were done in the modified intention-to-treat population (ie, included all patients randomly assigned to treatment who had at least one post-baseline CT scan and excluded those who did not receive study medication and who had any major violation of the eligible criteria). Safety was assessed in all patients who received any study treatment. This study is registered with ClinicalTrials.gov, NCT02592746, and is now complete. FINDINGS: Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled. 184 patients were randomly assigned to the palbociclib plus endocrine therapy group (n=92) or the capecitabine group (n=92), of whom 174 were included in the modified intention-to-treat population (n=90 in the palbociclib plus endocrine therapy group and n=84 in the capecitabine group). All patients were female and ethnicity data were not collected. As of data cutoff (Feb 29, 2024), median follow-up was 54·0 months (IQR 34·1-74·4). Median progression-free survival was 19·5 months (90% CI 14·3-22·2) for palbociclib plus endocrine therapy and 14·0 months (11·7-18·7) for capecitabine (hazard ratio 0·74 [90% CI 0·57-0·98]; one-sided log-rank p=0·036). 52 (58%) of 90 patients in the palbociclib plus endocrine therapy group and 48 (57%) of 84 in the capecitabine group died, with a median overall survival of 54·8 months (95% CI 48·9-77·1) in the palbociclib plus endocrine therapy group versus 57·8 months (46·3-89·2) in the capecitabine group (hazard ratio 1·02 [95% CI 0·69-1·51]; p=0·92). The most common grade 3 or worse adverse event was neutropenia (59 [64%] of 92 in the palbociclib plus endocrine therapy group vs 15 [18%] of 85 in the capecitabine group) . No treatment-related deaths occurred. INTERPRETATION: With extended follow-up, palbociclib plus exemestane with ovarian function suppression continued to show a significant benefit in progression-free survival compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who had been previously treated with tamoxifen; however, no improvement in overall survival was seen. Given the progression-free survival benefit, the upfront use of palbociclib plus endocrine therapy is the preferred option for premenopausal women, although a capecitabine-first strategy might be an alternative treatment strategy for maintaining overall survival in resource-limited settings. FUNDING: Pfizer and Ministry of Health & Welfare, South Korea.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Ahn HK, Kim JY, Lee KH, et al. Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study. Lancet Oncol. 2025. PMID: 39978378. doi:10.1016/S1470-2045(25)00006-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。